Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

The Effect of Alcohol on ABCA1 Expression and Lipid Metabolism

This study has been terminated.
(It was found that 20g of alcohol daily had no effect on ABCA1 expression or HDL levels.)
Sponsor:
Information provided by:
Bayside Health
ClinicalTrials.gov Identifier:
NCT00558935
First received: November 14, 2007
Last updated: May 9, 2011
Last verified: May 2011
  Purpose

The purpose of this study is to investigate the effects of red wine on ABCA1 levels


Condition Intervention
Type 2 Diabetes
Heart Disease
Dietary Supplement: Red Wine

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Double Blind (Subject, Caregiver, Investigator)
Primary Purpose: Prevention

Further study details as provided by Bayside Health:

Primary Outcome Measures:
  • measurements of dyslipidemia [ Time Frame: 2 years ]

Secondary Outcome Measures:
  • lipid functionality [ Time Frame: 2 years ]

Estimated Enrollment: 20
Study Start Date: October 2007
Study Completion Date: December 2008
Primary Completion Date: October 2008 (Final data collection date for primary outcome measure)
Intervention Details:
    Dietary Supplement: Red Wine
    20g alcohol daily/red wine for 4 weeks
  Eligibility

Ages Eligible for Study:   18 Years to 65 Years
Genders Eligible for Study:   Male
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Healthy participants
  • Aged 18-65 years
  • Free of overt coronary disease
  • BMI < 35
  • Fasting plasma glucose <6.1 mmol
  • Unmedicated
  • No major illness

Exclusion Criteria:

  • Unable to give informed consent
  • Smokers
  • Participants with alcoholism
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00558935

Locations
Australia, Victoria
Baker Heart Research Institute
Melbourne, Victoria, Australia, 3004
Sponsors and Collaborators
Bayside Health
Investigators
Principal Investigator: Bronwyn A Kingwell, PhD Baker Heart Research Institute
  More Information

No publications provided

ClinicalTrials.gov Identifier: NCT00558935     History of Changes
Other Study ID Numbers: 24/06
Study First Received: November 14, 2007
Last Updated: May 9, 2011
Health Authority: Australia: Human Research Ethics Committee

Additional relevant MeSH terms:
Diabetes Mellitus, Type 2
Heart Diseases
Cardiovascular Diseases
Diabetes Mellitus
Endocrine System Diseases
Glucose Metabolism Disorders
Metabolic Diseases

ClinicalTrials.gov processed this record on November 25, 2014